Scarica l'app Stockscreener
48.20
0.56%
0.27
Pre-mercato:
48.30
0.10
+0.21%
Precedente Chiudi:
$47.93
Aprire:
$48.24
Volume 24 ore:
748.11K
Relative Volume:
0.71
Capitalizzazione di mercato:
$3.87B
Reddito:
$541.74M
Utile/perdita netta:
$88.01M
Rapporto P/E:
44.37
EPS:
1.0862
Flusso di cassa netto:
$155.34M
1 W Prestazione:
+7.61%
1M Prestazione:
+6.10%
6M Prestazione:
+42.39%
1 anno Prestazione:
+34.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$43.90
$48.96
Portata 52W:
$29.45
$60.91
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
48.20 | 3.87B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-15 | Iniziato | Piper Sandler | Overweight |
| 2026-06-02 | Ripresa | Wolfe Research | Outperform |
| 2026-04-13 | Iniziato | Jefferies | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Underweight |
| 2025-10-20 | Iniziato | Canaccord Genuity | Hold |
| 2025-03-20 | Iniziato | Craig Hallum | Buy |
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Veracyte, Inc. Estimates – NASDAQ:VCYT - TradingView
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer - The Manila Times
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer - GlobeNewswire Inc.
Veracyte: Strong Diagnostic Growth And Improving Margins (NASDAQ:VCYT) - Seeking Alpha
Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com - Investing.com South Africa
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte, Inc. (VCYT) Stock forecasts - Yahoo Finance UK
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Veracyte Inc (VCYT) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 80/100 - GuruFocus
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Veracyte director Muna Bhanji sells $81,456 in company stock By Investing.com - Investing.com Nigeria
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research
Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com - Investing.com Nigeria
Veracyte director Muna Bhanji sells $81,456 in company stock - Investing.com
Director Muna Bhanji Sells 1,864 Shares of Veracyte Inc (VCYT) - GuruFocus
A director sold 1,864 Veracyte (VCYT) shares at $43.70 each under a trading plan. - Stock Titan
Veracyte presents six ESMO studies before results for Veracyte stock - ad-hoc-news.de
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 - The Manila Times
Researchers will present first evidence that a prostate test predicts who benefits from an added drug. - Stock Titan
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 - Moomoo
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte secures Medicare coverage: 11 analysts rate Veracyte stock - ad-hoc-news.de
A breast cancer test could spare chemotherapy for more than two-thirds of clinically high-risk patients - Stock Titan
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Veracyte Inc. Q3FY26 Results: Release date set for November 4 - scanx.trade
Veracyte, Inc. (VCYT) Stock forecasts - Yahoo Finance UK
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms - Zacks Investment Research
Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentals - ChartMill
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Is Veracyte Inc (VCYT) Overvalued After 3.7% Rally? GF Value Say - GuruFocus
Veracyte Inc. (VCYT) Key Financial Ratios – Valuation, Profitability & More - Value Research
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Bruker Gains 66.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Reasons to Hold HealthEquity Stock in Your Portfolio for Now - Zacks Investment Research
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies - Zacks Investment Research
Reasons to Add Globus Medical Stock to Your Portfolio Now - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research
Is This the Right Time to Add TMO Stock to Your Portfolio? - Zacks Investment Research
Cathie Wood’s ARK sells Teradyne stock, buys Veracyte - Investing.com
Veracyte Inc (VCYT) Shares Fall 6.3% -- What GF Score of 79 Tells Investors - GuruFocus
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up - TradingView
Veracyte stock falls 4.64 percent as Decipher data draw focus - AD HOC NEWS
Is It Prudent to Add Teleflex Stock to Your Portfolio Now? - Zacks Investment Research
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Veracyte Inc Azioni (VCYT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| JENS HOLSTEIN | Director |
Sep 24 '26 |
Proposed Sale |
47.00 |
7,500 |
352,500 |
0 |
| JOHN LEITE | Officer |
Sep 21 '26 |
Proposed Sale |
39.80 |
4,015 |
159,777 |
0 |
| Leite John | Global Chief Commercial Off |
Sep 21 '26 |
Sale |
40.00 |
4,015 |
160,600 |
124,329 |
| Holstein Jens | Director |
Sep 14 '26 |
Sale |
40.95 |
5,000 |
204,747 |
27,471 |
| JENS HOLSTEIN | Director |
Sep 14 '26 |
Proposed Sale |
40.95 |
5,000 |
204,747 |
0 |
| McGuire Annie | EVP, General Counsel |
Sep 04 '26 |
Sale |
43.09 |
3,254 |
140,212 |
131,160 |
| REBECCA CHAMBERS | Officer |
Sep 04 '26 |
Proposed Sale |
44.67 |
3,652 |
163,135 |
0 |
| Chambers Rebecca | Chief Financial Officer |
Sep 04 '26 |
Sale |
43.10 |
3,652 |
157,394 |
166,025 |
| ANN MCGUIRE | Officer |
Sep 04 '26 |
Proposed Sale |
44.67 |
3,254 |
145,356 |
0 |
| PHILLIP FEBBO | Officer |
Sep 04 '26 |
Proposed Sale |
44.67 |
13,110 |
585,624 |
0 |
0.16%
2.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):